ZYUS Life Sciences Provides Update on Clinical Trial Progress and Unit Private Placement

Executive Summary

• ZYUS Life Sciences announced that enrollment in its Phase 2a UTOPIA‑1 trial has reached the 25 % milestone, indicating steady progress toward the study’s target population.
• Preliminary safety and efficacy data from the trial are expected in early Q1 2026, providing a near‑term catalyst for the company.
• The company confirmed that its November 7, 2025 private placement raised $1,250,000.50 in gross proceeds (first tranche closed) and that no additional tranches are planned at this time, though other financing options remain under evaluation.

Key Details

• Trial Enrollment: 25 % of the intended patient cohort for UTOPIA‑1 has been enrolled across three active clinical sites.
• Study Focus: Phase 2a assessment of safety and preliminary analgesic efficacy of Trichomylin® softgel capsules in patients with advanced cancer experiencing moderate to severe pain.
• Data Timeline: Preliminary safety and efficacy results are anticipated in early Q1 2026.
• Clinical Trial Identifier: NCT06533657 (clinicaltrials.gov).
• Financing Summary:
• Total gross proceeds raised: $1,250,000.50.
• Structure: Non‑brokered private placement; first tranche closed on November 7, 2025.
• No further tranches are expected; the company may explore additional financing as needed.
• Management Quote: Brent Zettl, President and CEO, stated that reaching the 25 % enrollment milestone “underscores patient interest and the ongoing unmet needs of those experiencing cancer pain” and marks meaningful progress for the trial.

Notable Quotes

“We are pleased to have reached twenty‑five percent patient enrollment, a significant step that underscores patient interest and the ongoing unmet needs of those experiencing cancer pain,” – Brent Zettl, President & CEO.